

# UB-04 Form Billing and Coding Units

## J9289, injection, nivolumab, 2 mg and hyaluronidase-nvhy<sup>1</sup>

The sample form below is for informational purposes only.

ITEM NO.	REQUIRED INFORMATION	INFORMATION TO ENTER
Field Locator (FL) 43	Enter the modifier "N4" followed by the 11-digit NDC in positions 01-13. <sup>2</sup> Report quantity qualifier (ML) followed by quantity administered beginning in position 14. <sup>2</sup>	Example 1: N400003612001ML5 Example 2: N400003312001ML2.5
FL 44	Enter the appropriate HCPCS code and CPT code(s) for drug administration services. <sup>2</sup>	HCPCS code <sup>1</sup> : J9289      CPT code <sup>3</sup> : 96401 J9289, injection, nivolumab, 2 mg and hyaluronidase-nvhy <sup>1</sup>
FL 46	Billing units (service units) are reported here. <sup>2</sup>	Billing units <sup>1</sup> : 1 billing unit per 2 mg of nivolumab, with hyaluronidase-nvhy Example <sup>1,4</sup> : 600 mg nivolumab + 10,000 units hyaluronidase injection of OPDIVO Qvantig™: Enter 300 billing units.
FL 80	Some payers require detailed information about the drug in FL 80. <sup>2</sup> This may include: <ul style="list-style-type: none"> <li>• Drug name</li> <li>• Total dosage and strength</li> <li>• Method of administration</li> <li>• 11-digit NDC</li> </ul>	Drug name: OPDIVO QVANTIG™ (nivolumab and hyaluronidase-nvhy) Total dosage and strength: Specify total dosage given Method of administration: Subcutaneous Injection (SubQ or SC) 11-digit NDC <sup>4</sup> : 00003-3120-01 or 00003-6120-01 <b>Note that some payers may have character limits in FL 80, which may require abbreviations of the information included.</b>

### Sample UB-04 Form<sup>4</sup>

42 REV. CO.	43 DESCRIPTION	44 HCPCS / RATE / HIPPS CODE	45 SERV. DATE	46 SERV. UNITS
1 0636	N40003612001ML5	J9289-JZ	Date	300

Enter the appropriate NDC 5010 format here:

- N400003312001ML2.5
- N400003612001ML5

Enter total billing units here

Please contact the payer or BMS Access Support for additional information on coding and billing units.

In addition to coding specifics, some payers may require additional information, such as a drug purchase invoice or documentation of medical necessity. The accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and the patient.

Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item. Please contact the payer or BMS Access Support<sup>®</sup> for additional information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code. CPT<sup>®</sup> codes and descriptions are copyright 2025 American Medical Association (AMA). All rights reserved. CPT<sup>®</sup> is a registered trademark of the AMA.

**References:** 1. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Determinations: First Quarter, 2025 HCPCS Coding Cycle. Accessed September 15, 2025. <https://www.cms.gov/files/document/2025-hcpcs-application-summary-quarter-1-2025-drugs-and-biologicals.pdf> 2. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Chapter 25 – Completing and Processing the Form CMS-1450 Data Set. Revision 12423, December 20, 2023. Accessed September 15, 2025. <http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c25.pdf> 3. American Medical Association. CPT 2025 Professional Edition. American Medical Association; 2024. 4. OPDIVO Qvantig™ [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.